Target
multi-kinase inhibitor
6 abstracts
Abstract
International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).Org: Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Los Angeles, CA, Seoul National University Hospital, Seoul, South Korea,
Abstract
Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC).Org: Dana-Farber Cancer Institute, Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center, Yale Cancer Center, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
Long-term outcomes of anlotinib and penpulimab combined with chemotherapy in the treatment of patients with metastatic nasopharyngeal carcinoma that failed definitive platinum-based chemoradiotherapy.Org: Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China, The Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China, Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, China, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China,
Abstract
Efficacy and safety of donafenib combined with transcatheter arterial chemoembolization (TACE) and anti-PD1 antibody for the treatment of unresectable hepatocellular carcinoma (uHCC): A retrospective study.Org: Eastern Hepatobiliary Surgery Hospital, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Efficacy and safety of donafenib combined with transarterial chemoembolization (TACE) for treating intermediate/advanced-stage hepatocellular carcinoma (HCC): A retrospective real-world study.Org: University of Science and Technology of China,
Abstract
The preventive effect of celecoxib on regorafenib-associated hand-foot syndrome in patients with liver metastasis from colorectal cancer: A single-center, retrospective, real-world study.Org: Beijing Cancer Hospital & Institute, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China,